Remove Hospital Remove Quality of Life Remove Technology
article thumbnail

New Technology Promises to Revolutionize Valvular Heart Disease Care

DAIC

Getty Images milla1cf Mon, 04/01/2024 - 08:21 April 1, 2024 — Roughly 25,000 Americans die each year from valvular heart disease, but researchers from Rutgers Health and other institutions conclude that new technology could soon help doctors slash that number. “We

article thumbnail

Abbott Announces FDA Approval of First-of-its-kind Device to Repair Leaky Tricuspid Heart Valve, TriClip

DAIC

Data from the TRILUMINATE Pivotal trial demonstrated that patients who received TriClip experienced a marked improvement in the severity of their symptoms and quality of life, with benefits sustained at one year. are affected by tricuspid regurgitation, 1 which can severely impact quality of life. Abbott has announced U.S

Tricuspid 105
article thumbnail

HRS 2024: Innovation Meets Reality

DAIC

Innovation in medical technology exists to improve patient outcomes, increase surgical efficiency and enhance patient safety. Infrequently, we see medical technology innovation of a paradigmatic nature that changes the way physicians approach disease states and dramatically improve results.

article thumbnail

Rationale and Design of the mTECH?Rehab Randomized Controlled Trial: Impact of a Mobile Technology Enabled Corrie Cardiac Rehabilitation Program on Functional Status and Cardiovascular Health

Journal of the American Heart Association

Key secondary and exploratory outcomes include improvement in a composite cardiovascular health metric, CR engagement, quality of life, health factors (including low‐density lipoprotein‐cholesterol, hemoglobin A1c, weight, diet, smoking cessation, blood pressure), and psychosocial factors.

article thumbnail

Randomised trial of app-led motivational support for patients with AF to promote weight loss (MOTIVATE-AF)

The British Journal of Cardiology

This randomised study set out to examine if smartphone-based app technology could increase weight loss in a patient population with obesity and AF. Individuals were screened following outpatient referral to Leeds Teaching Hospitals NHS Trust for symptomatic AF. Sixty-four patients underwent randomisation.

article thumbnail

CVRx Announces Availability of Additional Data Supporting Long-term Benefits of Barostim

DAIC

Dr. JoAnn Lindenfeld of Vanderbilt University presented analysis showing that patients with Barostim + GDMT had sustained and significant improvements in quality-of-life scores (MLWHF and EQ-5D) and many subdomains of these scores (e.g., See more details at TCTMD. versus patients on GDMT alone.

article thumbnail

BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study

DAIC

CMS previously published a New Technology APC (Ambulatory Payment Classifications) code that covers the CardiAMP Cell Therapy investigational study procedure, including the BioCardia investigational products utilized to perform the study procedure, allowing the study centers to be reimbursed for the study procedure and products.

CMS 111